{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-022401","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2026-05-12T12:05:36+00:00","discovered_at":"2026-05-12T12:10:00.383265+00:00","generated_at":"2026-05-12T12:14:21.791242+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Imunon reports Q1 net loss $4.3M; Phase 2 ovarian data shows 14.7-month OS improvement","bullets":["Net loss of $4.3M ($0.84 per share) vs $4.1M ($3.15 per share) in Q1 2025; cash $4.8M at March 31, 2026.","Phase 2 OVATION 2 final data: median OS 45.1 vs 30.4 months (+14.7 months) for IMNN-001+SoC vs SoC alone.","With PARP inhibitor maintenance, median OS 65.6 vs 41.4 months (+24.2 months) for IMNN-001 arm.","Phase 3 OVATION 3 enrollment expected to complete by Q1 2029; FDA aligned on BLA path.","Strategic reorganization in Feb 2026 reduced operating expenses; R&D expenses up to $2.3M from $2.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022401","json":"https://secwatch.observer/filing/0001493152-26-022401.json","markdown":"https://secwatch.observer/filing/0001493152-26-022401.md","text":"https://secwatch.observer/filing/0001493152-26-022401.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315226022401/0001493152-26-022401-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315226022401/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T12:14:21.791242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"edf0d031270e1566fb79286a90f891e8106f3f6e","claim":"Imunon, Inc. reported the three months ended March 31, 2026 results: net income $4.3 million, EPS $0.84 per share.","evidence_excerpt":"Net loss for the first quarter of 2026 was $4.3 million, or $0.84 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315226022401/0001493152-26-022401-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2026"},{"label":"Net income","value":"$4.3 million"},{"label":"EPS","value":"$0.84 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}